|
Glenn C. Michelson M.D. joined Sunesis in 2006 as Senior Director and Head of Clinical Science Oncology bringing more than a decade of experience as a medical oncologist and in drug development in both industry and academic settings. Promoted to the position of Vice President Clinical Strategy in 2008 he oversees the clinical development of Sunesis' novel cancer therapeutics with an emphasis on the planning and execution of late-stage clinical studies focused on regulatory approval. From 2004 to 2006 Dr. Michelson served as Director in the Clinical Oncology Therapeutic Unit at Chiron Corporation (now Novartis AG) where he served as Medical Director and as lead clinician for the company's kinase programs. Previously he was Medical Director Clinical Development for Cell Therapeutics Inc. where he was responsible for Phase 3 studies of Xyotax®. Dr. Michelson began his pharmaceutical industry career at Pfizer Global Research and Development (formerly Agouron) from 1998 to 2003 where he led Phase 1 through Phase 3 clinical development programs in oncology. Dr. Michelson has held faculty positions at the University of California San Diego and at the University of Louisville and has been a Principal Investigator for a number of clinical trials. He received both his M.D. and B.A. in Chemistry from the University of Louisville. | 